- Novel 3-Oxazolidinedione-6-aryl-pyridinones as Potent, Selective, and Orally Active EP3 Receptor Antagonists
[作者:JIN JIAN; MORALESRAMOS ANGEL; EIDAM PATRICK; MECOM JOHN; LI YUE; BROOKS CARL; HILFIKER MARK; ZHANG DAVID; WANG NING; SHI DONGCHUAN; TSENG PEISAN; WHELESS KAREN; BUDZIK BRIAN; EVANS KAREN; JAWORSKI JONPAUL; JUGUS JACK; LEON LISA; WU CHARLENE; PULLEN MARK; KARAMSHI BHUMIKA; RAO PARVATHI; WARD EMMA; LAPING NICHOLAS; EVANS CHRISTOPHER; LEACH COLIN; HOLT DENNIS; SU XIN; MORROW DWIGHT; FRIES HARVEY; THORNELOE KEVIN; EDWARDS RICHARD,期刊:ACS Medicinal Chemistry Letters, 页码:316-320 , 文章类型: Article,,卷期:2010年1-7]
- High-throughput screening and subsequent optimization led to the discovery of novel 3-oxazolidinedione-6-aryl-pyridinones exemplified by compound 2 as potent and selective EP3-antagonists with excellent pharmacokinetic p...
- Discovery of Potent and Selective Inhibitors of CDPK1 from C. parvum and T. gondii
[作者:MURPHY RYAN C; OJO KAYODE K; LARSON ERIC T; CASTELLANOSGONZALEZ ALEJANDRO; PERERA B GAYANI K; KEYLOUN KATELYN R; KIM JESSICA E; BHANDARI JANHAVI G; MULLER NATASCHA R; VERLINDE CHRISTOPHE L M J; WHITE A CLINTON JR; MERRITT ETHAN A; VAN VOORHIS WESLEY C; MALY DUSTIN J,期刊:ACS Medicinal Chemistry Letters, 页码:331-335 , 文章类型: Article,,卷期:2010年1-7]
- The protozoans Cryptosporidium parvum and Toxoplasma gondii are parasites of major health concern to humans. Both parasites contain a group of calcium dependent protein kinases (CDPKs) which are found in plants and cilia...
- Structure-Activity Study of Dihydrocinnamic Acids and Discovery of the Potent FFA1 (GPR40) Agonist TUG-469
[作者:CHRISTIANSEN ELISABETH; DUEHANSEN MARIA E; URBAN CHRISTIAN; MERTEN NICOLE; PFLEIDERER MICHAEL; KARLSEN KASPER K; RASMUSSEN SANNE S; STEENSGAARD METTE; HAMACHER ALEXANDRA; SCHMIDT JOHANNES; DREWKE CHRISTEL; PETERSEN RASMUS KOEFOED; KRISTIANSEN KARSTEN; ULLRICH SUSANNE; KOSTENIS EVI; KASSACK MATTHIAS U; ULVEN TROND,期刊:ACS Medicinal Chemistry Letters, 页码:345-349 , 文章类型: Article,,卷期:2010年1-7]
- The free fatty acid 1 receptor (FFA1 or GPR40), which is highly expressed on pancreatic beta-cells and amplifies glucose-stimulated insulin secretion, has emerged as attractive target for the treatment of type 2 diabetes...
- Identification of an Orally Bioavailable, Potent, and Selective Inhibitor of GlyT1
[作者:BLACKABY WESLEY P; LEWIS RICHARD T; THOMSON JOANNE L; JENNINGS ANDREW S R; GOODACRE SIMON C; STREET LESLIE J; MACLEOD ANGUS M; PIKE ANDREW; WOOD SUZANNE; THOMAS STEVE; BROWN TERRY A; SMITH ALISON; PILLAI GOPALAN; ALMOND SARAH; GUSCOTT MARTIN R; BURNS H DONALD; ENG WAISI; RYAN CHRISTINE; COOK JACQUELYNN; HAMILL TERENCE G,期刊:ACS Medicinal Chemistry Letters, 页码:350-354 , 文章类型: Article,,卷期:2010年1-7]
- Amalgamation of the structure-activity relationship of two series of GlyT1 inhibitors developed at Merck led to the discovery of a clinical candidate, compound 16 (DCCCyB), which demonstrated excellent in vivo occupancy ...
|